NZ608120A - Deuterated analogs of pridopidine useful as dopaminergic stabilizers - Google Patents
Deuterated analogs of pridopidine useful as dopaminergic stabilizersInfo
- Publication number
- NZ608120A NZ608120A NZ60812011A NZ60812011A NZ608120A NZ 608120 A NZ608120 A NZ 608120A NZ 60812011 A NZ60812011 A NZ 60812011A NZ 60812011 A NZ60812011 A NZ 60812011A NZ 608120 A NZ608120 A NZ 608120A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pridopidine
- deuterated analogs
- useful
- analogs
- deuterium
- Prior art date
Links
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title abstract 5
- 229950003764 pridopidine Drugs 0.000 title abstract 4
- 230000003291 dopaminomimetic effect Effects 0.000 title 1
- 239000003381 stabilizer Substances 0.000 title 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 229910052805 deuterium Inorganic materials 0.000 abstract 2
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 229940088679 drug related substance Drugs 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000001294 propane Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201070385 | 2010-09-03 | ||
| US38085110P | 2010-09-08 | 2010-09-08 | |
| PCT/EP2011/064954 WO2012028635A1 (en) | 2010-09-03 | 2011-08-31 | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ608120A true NZ608120A (en) | 2014-12-24 |
Family
ID=44653278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ60812011A NZ608120A (en) | 2010-09-03 | 2011-08-31 | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20130197031A1 (enExample) |
| EP (1) | EP2611759A1 (enExample) |
| JP (1) | JP2013536825A (enExample) |
| KR (1) | KR20140008297A (enExample) |
| CN (1) | CN103249697B (enExample) |
| AU (2) | AU2011298382A1 (enExample) |
| BR (1) | BR112013005125A2 (enExample) |
| CA (1) | CA2810092A1 (enExample) |
| CL (1) | CL2013000604A1 (enExample) |
| EA (1) | EA201390332A1 (enExample) |
| IL (1) | IL224776A (enExample) |
| MX (1) | MX2013002453A (enExample) |
| NZ (1) | NZ608120A (enExample) |
| PE (1) | PE20140105A1 (enExample) |
| PH (1) | PH12013500406A1 (enExample) |
| SG (2) | SG188298A1 (enExample) |
| WO (1) | WO2012028635A1 (enExample) |
| ZA (1) | ZA201301902B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| MX2009011020A (es) * | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX343620B (es) | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| JP6362601B2 (ja) | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| MX2016010213A (es) | 2014-02-07 | 2017-04-13 | Auspex Pharmaceuticals Inc | Formulaciones farmaceuticas novedosas. |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| PL3265085T3 (pl) * | 2015-03-06 | 2022-11-07 | Auspex Pharmaceuticals, Inc. | Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| EP3419622B1 (en) | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| ES2972205T3 (es) | 2017-01-20 | 2024-06-11 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento del síndrome x frágil |
| US10459055B2 (en) * | 2017-04-07 | 2019-10-29 | Case Western Reserve University | System and method for reduced field of view MR fingerprinting for parametric mapping |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| JP2020532517A (ja) | 2017-08-30 | 2020-11-12 | プリレニア ニューロセラピューティクス リミテッド | 高濃度プリドピジン製剤 |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| EP4741013A3 (en) | 2020-02-13 | 2026-08-05 | Prilenia Neurotherapeutics Ltd. | Combination therapy for treating amyotrophic lateral sclerosis using pridopidine and another active agent |
| JP7603713B2 (ja) | 2020-05-04 | 2024-12-20 | プリレニア ニューロセラピューティクス リミテッド | 選択的ｓ１ｒアゴニストを使用するウイルス感染、疾患、又は障害の治療 |
| CN115666467A (zh) | 2020-05-20 | 2023-01-31 | 恩塔米克控股有限公司 | 管理睑板腺功能不足的方法和装置 |
| IL298334A (en) * | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| WO2026080658A1 (en) | 2024-10-10 | 2026-04-16 | Prilenia Therapeutics Inc. | Pridopidine for the treatment of distal hereditary motor neuropathy (dhmn) |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| DE10123129A1 (de) * | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| US7004629B2 (en) | 2003-07-26 | 2006-02-28 | Arthur Joseph Shrader | Method and apparatus for hanging a resealable bag |
| CA2569843A1 (en) | 2004-06-08 | 2005-12-22 | A. Carlsson Research Ab | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| US20070112031A1 (en) | 2005-11-14 | 2007-05-17 | Gant Thomas G | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| CN101360742A (zh) * | 2005-11-14 | 2009-02-04 | 奥斯拜客斯制药有限公司 | 具有血清素源性活性和增强的治疗特性的取代苯基哌啶 |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| US20100197712A1 (en) * | 2007-06-18 | 2010-08-05 | Arvid Carlsson | Use of dopamine stabilizers |
| US8288414B2 (en) * | 2007-09-12 | 2012-10-16 | Deuteria Pharmaceuticals, Inc. | Deuterium-enriched lenalidomide |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX343620B (es) | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| MX2015003812A (es) | 2012-09-27 | 2015-07-17 | Teva Pharma | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. |
| US20150209346A1 (en) | 2012-09-27 | 2015-07-30 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2937243C (en) | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| WO2017015515A1 (en) | 2015-07-23 | 2017-01-26 | Knowles Electronics, Llc | Microphone with temperature sensor |
| EP3419622B1 (en) | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| CN109906270A (zh) | 2016-09-16 | 2019-06-18 | 嘉吉公司 | 经遗传修饰的乳酸消耗酵母以及使用此类经遗传修饰的酵母的发酵工艺 |
| ES2972205T3 (es) | 2017-01-20 | 2024-06-11 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento del síndrome x frágil |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| NL2019473B1 (en) | 2017-09-01 | 2019-03-11 | Isobionics B V | Terpene Synthase producing patchoulol and elemol, and preferably also pogostol |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
-
2011
- 2011-08-31 NZ NZ60812011A patent/NZ608120A/en not_active IP Right Cessation
- 2011-08-31 SG SG2013014022A patent/SG188298A1/en unknown
- 2011-08-31 EA EA201390332A patent/EA201390332A1/ru unknown
- 2011-08-31 US US13/820,024 patent/US20130197031A1/en not_active Abandoned
- 2011-08-31 EP EP20110757801 patent/EP2611759A1/en not_active Withdrawn
- 2011-08-31 AU AU2011298382A patent/AU2011298382A1/en not_active Abandoned
- 2011-08-31 PE PE2013000359A patent/PE20140105A1/es not_active Application Discontinuation
- 2011-08-31 WO PCT/EP2011/064954 patent/WO2012028635A1/en not_active Ceased
- 2011-08-31 BR BR112013005125A patent/BR112013005125A2/pt not_active IP Right Cessation
- 2011-08-31 PH PH1/2013/500406A patent/PH12013500406A1/en unknown
- 2011-08-31 KR KR20137007971A patent/KR20140008297A/ko not_active Ceased
- 2011-08-31 CN CN201180042460.5A patent/CN103249697B/zh active Active
- 2011-08-31 SG SG10201506761XA patent/SG10201506761XA/en unknown
- 2011-08-31 CA CA 2810092 patent/CA2810092A1/en not_active Abandoned
- 2011-08-31 MX MX2013002453A patent/MX2013002453A/es active IP Right Grant
- 2011-08-31 JP JP2013526452A patent/JP2013536825A/ja active Pending
-
2013
- 2013-02-18 IL IL224776A patent/IL224776A/en not_active IP Right Cessation
- 2013-03-01 CL CL2013000604A patent/CL2013000604A1/es unknown
- 2013-03-13 ZA ZA2013/01902A patent/ZA201301902B/en unknown
-
2015
- 2015-12-14 US US14/968,510 patent/US20160095847A1/en not_active Abandoned
- 2015-12-14 US US14/968,522 patent/US20160166559A1/en not_active Abandoned
-
2016
- 2016-10-26 AU AU2016250390A patent/AU2016250390A1/en not_active Abandoned
-
2018
- 2018-04-23 US US15/960,041 patent/US20180235950A1/en not_active Abandoned
- 2018-09-17 US US16/133,192 patent/US10799492B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103249697B (zh) | 2016-06-15 |
| BR112013005125A2 (pt) | 2016-08-16 |
| KR20140008297A (ko) | 2014-01-21 |
| MX2013002453A (es) | 2013-08-01 |
| SG10201506761XA (en) | 2015-10-29 |
| PH12013500406A1 (en) | 2019-07-17 |
| US20160095847A1 (en) | 2016-04-07 |
| US20180235950A1 (en) | 2018-08-23 |
| IL224776A (en) | 2017-07-31 |
| SG188298A1 (en) | 2013-04-30 |
| US20190015401A1 (en) | 2019-01-17 |
| US10799492B2 (en) | 2020-10-13 |
| US20160166559A1 (en) | 2016-06-16 |
| ZA201301902B (en) | 2014-05-28 |
| AU2016250390A1 (en) | 2016-11-10 |
| AU2011298382A1 (en) | 2013-05-02 |
| CL2013000604A1 (es) | 2013-11-15 |
| PE20140105A1 (es) | 2014-02-14 |
| WO2012028635A1 (en) | 2012-03-08 |
| JP2013536825A (ja) | 2013-09-26 |
| CA2810092A1 (en) | 2012-03-08 |
| EP2611759A1 (en) | 2013-07-10 |
| US20130197031A1 (en) | 2013-08-01 |
| EA201390332A1 (ru) | 2013-08-30 |
| CN103249697A (zh) | 2013-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013500406A1 (en) | Deuterated analogs of pridopidine useful as dopaminergic stabilizers | |
| CY1124117T1 (el) | Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων | |
| UA105671C2 (uk) | Фармацевтична композиція, яка містить похідне хіноліну | |
| CY1117996T1 (el) | Genz 112638 για την θεραπευτικη αγωγη της νοσου gaucher ή fabry σε θεραπεια συνδυασμου | |
| CY1118088T1 (el) | Παραγωγο πουρινονης ως εκλεκτικος αναστολεας βτκ κινασης | |
| NZ601121A (en) | 5-alkynyl-pyrimidines | |
| BR112014015363A2 (pt) | derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos | |
| BR112012017580A2 (pt) | derivados de heteroarila contendo nitrogênio | |
| IN2014MN01755A (enExample) | ||
| EA201390381A1 (ru) | Триазиноксадиазолы | |
| MX2011013884A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas. | |
| MX2013001614A (es) | Compuestos heterociclico. | |
| NZ601483A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112014018959A8 (pt) | Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer | |
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| BR112015006436A2 (pt) | novas piridinonas bicíclicas | |
| PH12013500942A1 (en) | Triazolopyridine compounds | |
| MA34055B1 (fr) | Chlorhydrate d'agomelatine hydrate et sa preparation | |
| MX361458B (es) | Compuestos de pirimido-piridazinona y uso de los mismos. | |
| BR112014031091A2 (pt) | Derivados de piperidina para agonista de gpr119 | |
| TN2009000275A1 (en) | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | |
| MX2011008360A (es) | Derivados de piridazinona sustituida con heteroarilo. | |
| CY1115987T1 (el) | Θεραπευτικες εφαρμογες στον καρδιαγγειακο τομεα των παραγωγων κιναζολινεδιονης | |
| NZ702835A (en) | 3-o-heteroaryl-ingenol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| ERR | Error or correction |
Free format text: THE OWNER HAS BEEN CORRECTED TO 3049443, IVAX INTERNATIONAL GMBH, ALPENSTRASSE 2, RAPPERSWIL 8640, CH Effective date: 20150417 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 AUG 2016 BY DENNEMEYER + CO. Effective date: 20150721 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 AUG 2017 BY DENNEMEYER + CO. Effective date: 20160722 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 AUG 2018 BY DENNEMEYER + CO Effective date: 20170726 |
|
| LAPS | Patent lapsed |